0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Dupixent Approvals Expand Regeneron's Immunology Reach And Valuation Debate [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Regeneron Pharmaceuticals (NasdaqGS:REGN) and Sanofi received FDA approval for Dupixent to treat allergic fungal rhinosinusitis in adults and children. This is the first FDA approval for a treatment specifically targeting allergic fungal rhinosinusitis. The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending Dupixent for pediatric chronic spontaneous urticaria in the EU. Regeneron, through its partnership with Sanofi, has built Dupixent into a key drug in allergic and inflammatory diseases, and these decisions add two more indications to that story. For investors watching NasdaqGS:REGN, the latest approvals expand Dupixent's potential reach into conditions where treatment options can be limited, especially for younger patients. They also reinforce the company's focus on immunology alongside its e [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

Dupixent Approvals Expand Regeneron's Immunology Reach And Valuation Debate [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Regeneron Pharmaceuticals (NasdaqGS:REGN) and Sanofi received FDA approval for Dupixent to treat allergic fungal rhinosinusitis in adults and children. This is the first FDA approval for a treatment specifically targeting allergic fungal rhinosinusitis. The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending Dupixent for pediatric chronic spontaneous urticaria in the EU. Regeneron, through its partnership with Sanofi, has built Dupixent into a key drug in allergic and inflammatory diseases, and these decisions add two more indications to that story. For investors watching NasdaqGS:REGN, the latest approvals expand Dupixent's potential reach into conditions where treatment options can be limited, especially for younger patients. They also reinforce the company's focus on immunology alongside its e [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS